Latest Period
Q1 2026
Security Snapshot
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) Institutional Ownership
CUSIP: 492327101
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
148
Shares (Excl. Options)
18,564,379
Price
$11.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KROS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 18,564,379
- Total 13F value
- $204,931,904
- Portfolio coverage rank
- 0%
- Share change
- -1,605,548
- Value change
- -$29,235,035
- Number of holders
- 148
- Shares outstanding
- 19,716,217
- SEC-reported price per share
- $10.70
- Insider filing price
- $10.70
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 492327101.
- 148 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 148 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $204,931,904 to $524,300.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 148 institutions filings for Q1 2026.
Security key
492327101
Latest holder period
Q1 2026
13F holders
148
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
KROS full holder history
Keros Therapeutics, Inc. SEC filings
Keros Therapeutics, Inc. company facts
Keros Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 492327101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
KROS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | $21,971,928 | 1,990,842 | BlackRock, Inc. | 31 Mar 2026 | |||
| Nantahala Capital Management, LLC | 6.9% | $17,073,258 | 1,360,419 | Nantahala Capital Management, LLC | 31 Mar 2026 | |||
| ALKEON CAPITAL MANAGEMENT LLC | 2.7% | $15,645,210 | 1,101,000 | Alkeon Capital Management LLC | 31 Dec 2024 | |||
| Madison Avenue Partners, LP | 2.7% | -62% | $16,062,286 | -$34,918,552 | 823,707 | -68% | Madison Avenue International LP | 31 Dec 2025 |
| D. E. SHAW & CO, L.P. | 3.9% | -24% | $14,745,042 | -$15,400,944 | 756,156 | -51% | D. E. Shaw & Co., L.P. | 31 Dec 2025 |
| FMR LLC | 1.7% | $10,010,547 | 704,472 | FMR LLC | 31 Jan 2025 | |||
| JPMORGAN CHASE & CO | 0.2% | -102% | $1,617,141 | -$35,146,204 | 113,803 | -96% | JPMORGAN CHASE & CO. | 30 Apr 2025 |
| ExodusPoint Capital Management, LP | 0.04% | -104% | $260,520 | -$36,943,510 | 13,360 | -99% | ExodusPoint Capital Management, LP | 31 Dec 2025 |
As of 31 Mar 2026, 148 institutional investors reported holding 18,564,379 shares of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS). This represents 94% of the company’s total 19,716,217 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 2,411,793 | +5.3% | 0% | $26,626,189 |
| Nantahala Capital Management, LLC | 6.9% | 1,360,419 | +277% | 0.94% | $15,019,026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 831,421 | 0% | 0% | $9,178,888 |
| ORBIMED ADVISORS LLC | 3.9% | 759,155 | -5.6% | 0.19% | $8,381,071 |
| Qube Research & Technologies Ltd | 3.7% | 724,926 | -7.5% | 0.01% | $8,003,183 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3.6% | 706,071 | -8.1% | 0.03% | $7,795,024 |
| FEDERATED HERMES, INC. | 3.5% | 689,229 | +5.3% | 0.01% | $7,609,089 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 682,043 | 0% | 0% | $7,529,755 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5% | 681,460 | +7.3% | 0% | $7,524,833 |
| Madison Avenue Partners, LP | 3.2% | 626,583 | -24% | 0.3% | $6,917,476 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3% | 590,249 | -56% | 0% | $6,516,349 |
| STATE STREET CORP | 2.8% | 561,730 | -48% | 0% | $6,201,499 |
| D. E. Shaw & Co., Inc. | 2.6% | 509,608 | -33% | 0% | $5,626,072 |
| RENAISSANCE TECHNOLOGIES LLC | 2.3% | 453,482 | -23% | 0.01% | $5,006,441 |
| CITADEL ADVISORS LLC | 2.1% | 406,666 | -14% | 0% | $4,489,592 |
| AQR CAPITAL MANAGEMENT LLC | 2.1% | 406,563 | +125% | 0% | $4,488,455 |
| TWO SIGMA INVESTMENTS, LP | 1.8% | 363,835 | +14% | 0% | $4,016,738 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 321,360 | +454% | 0% | $3,547,031 |
| Nuveen, LLC | 1.3% | 262,075 | +315% | 0% | $2,893,308 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.3% | 257,884 | -20% | 0.01% | $2,847,039 |
| NORTHERN TRUST CORP | 1.3% | 254,187 | +1.4% | 0% | $2,806,224 |
| Man Group plc | 1.2% | 238,618 | +25% | 0.01% | $2,634,343 |
| GOLDMAN SACHS GROUP INC | 1.1% | 224,479 | -62% | 0% | $2,478,248 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.99% | 195,017 | +225% | 0.04% | $2,152,988 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.91% | 179,952 | -3.7% | 0% | $1,986,670 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q1 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 49,000 | $524,300 | -$1,238,374 | $10.70 | 2 |
| 2026 Q1 | 18,564,379 | $204,931,904 | -$29,235,035 | $11.04 | 148 |
| 2025 Q4 | 20,068,584 | $408,418,044 | -$274,897,076 | $20.36 | 163 |
| 2025 Q3 | 35,272,212 | $558,014,186 | -$7,638,925 | $15.82 | 151 |
| 2025 Q2 | 35,922,272 | $479,567,957 | +$53,894,426 | $13.35 | 134 |
| 2025 Q1 | 32,796,190 | $334,208,916 | -$101,548,195 | $10.19 | 154 |
| 2024 Q4 | 36,741,918 | $581,640,265 | -$99,583,348 | $15.83 | 159 |
| 2024 Q3 | 34,948,467 | $2,029,993,469 | +$197,656,348 | $58.07 | 162 |
| 2024 Q2 | 31,483,081 | $1,437,735,495 | -$1,704,535 | $45.70 | 150 |
| 2024 Q1 | 31,378,208 | $2,077,197,760 | +$376,189,592 | $66.20 | 144 |
| 2023 Q4 | 25,748,679 | $1,023,986,857 | +$107,389,201 | $39.76 | 119 |
| 2023 Q3 | 22,915,590 | $730,562,303 | +$10,983,703 | $31.88 | 106 |
| 2023 Q2 | 22,423,232 | $900,980,099 | +$13,493,306 | $40.18 | 121 |
| 2023 Q1 | 22,003,238 | $936,983,921 | +$94,494,039 | $42.70 | 128 |
| 2022 Q4 | 19,814,952 | $951,517,038 | +$88,887,412 | $48.02 | 122 |
| 2022 Q3 | 18,166,429 | $683,394,048 | +$33,259,877 | $37.62 | 107 |
| 2022 Q2 | 17,360,328 | $479,673,115 | +$10,253,619 | $27.63 | 101 |
| 2022 Q1 | 16,425,972 | $892,979,574 | +$13,785,386 | $54.38 | 101 |
| 2021 Q4 | 16,155,340 | $944,400,680 | +$68,408,989 | $58.51 | 96 |
| 2021 Q3 | 13,732,777 | $543,300,250 | -$15,835,150 | $39.56 | 86 |
| 2021 Q2 | 14,120,390 | $599,680,759 | -$43,588,395 | $42.47 | 79 |
| 2021 Q1 | 14,412,080 | $887,014,019 | -$122,639,102 | $61.55 | 83 |
| 2020 Q4 | 16,029,747 | $1,129,296,879 | +$301,336,670 | $70.54 | 81 |
| 2020 Q3 | 11,780,724 | $454,579,430 | +$33,779,230 | $38.57 | 49 |
| 2020 Q2 | 10,926,163 | $409,790,602 | +$409,790,602 | $37.51 | 51 |